Replimune Group (REPL) Akcie Kurz

Replimune Group Kurz

NASDAQ·UZAVŘENO
19,23
​
Trh uzavřen

Medián cílové ceny analytiků je 19,00 USD, tedy pod aktuální cenu o 1,2 %. Z 15 analytiků jich 13 doporučuje nákup — celkový konsenzus je Koupit.

Cena akcie Replimune Group

Tato data přes Eulerpool API

100 000 požadavků/měs. zdarma · bez karty

Obchodní model Replimune Group a analýza akcií

Společnost Replimune Group Inc je americká biotechnologická společnost se sídlem ve Woburnu v Massachusetts. Zaměřuje se na vývoj terapeutik pro léčbu rakoviny pomocí onkolytických virů.

Nejčastější otázky týkající se akcie Replimune Group

Replimune Group Inc operates under a business model focused on developing and commercializing oncolytic immunotherapies for the treatment of cancer. The company's innovative approach involves the use of its proprietary platform, called Immulytic™, which is designed to enhance the body's immune response against tumors. Replimune's therapies are aimed at both solid tumors and hematologic malignancies, with a focus on providing patients with a potentially transformative treatment option. By leveraging its deep understanding of immunology and expertise in viral-based therapeutics, Replimune Group Inc strives to make a significant impact in the fight against cancer.

Replimune Group Inc primarily operates in the biotechnology industry.

The main competitors of Replimune Group Inc in the market are established pharmaceutical companies with a focus on developing oncolytic immunotherapies. These competitors include leading players in the biotechnology sector such as Amgen, Inc., Merck & Co., Inc., and Bristol Myers Squibb Company. Replimune Group Inc, a clinical-stage biotechnology company, aims to leverage its innovative immuno-oncology platform to develop next-generation cancer treatments. With its unique portfolio and cutting-edge technologies, Replimune Group Inc strives to distinguish itself among its industry counterparts and contribute to advancements in the field of oncolytic immunotherapies.

Replimune Group Inc is a pioneering biotechnology company focused on developing innovative cancer therapeutics. Founded in 2015, Replimune is dedicated to harnessing the power of oncolytic immunotherapies to treat a wide range of solid tumors. The company's novel approach involves engineering a specific virus to selectively replicate and destroy cancer cells while stimulating the immune response. Replimune's groundbreaking technology, known as Immulytic™, has shown promising results in early-stage clinical trials for various cancers. With a strong commitment to advancing patient care and improving outcomes, Replimune Group Inc is poised to make significant contributions to the field of cancer treatment.

Replimune Group Inc has achieved numerous significant milestones. The company successfully completed its initial public offering (IPO) in July 2018, raising funds to support its research and development activities. In September 2019, Replimune reported positive preliminary data from its Phase 1 clinical trials of RP1 in combination with nivolumab for advanced solid tumors. Later, in May 2020, the company announced positive overall survival data from the Phase 2 portion of the same trial. Replimune also received Fast Track designation from the U.S. FDA for RP1 in advanced cutaneous squamous cell carcinoma. These milestones demonstrate the company's progress, innovation, and potential for future growth.

Replimune Group Inc is primarily present in the United States.

Replimune Group Inc represents values of innovation, integrity, and patient-centricity. With a strong corporate philosophy, they focus on developing oncolytic immunotherapies to combat cancer. The company is dedicated to advancing cutting-edge science and technology to provide effective and transformative treatments for patients. Replimune Group Inc strives to deliver innovative solutions that address unmet medical needs and improve the quality of life for cancer patients. Emphasizing collaboration, they work closely with industry partners and medical professionals to advance their research and impact the lives of millions affected by cancer.

Analytici aktuálně stanovují průměrnou cílovou cenu 18,67 USD pro akcii Replimune Group (medián: 19,00 USD), tedy -4,9 % vůči poslední ceně. Konsensus vychází z 15 hodnocení analytiků.

15 analytiků aktuálně hodnotí akcii Replimune Group: 13 doporučuje koupit, 1 držet a 1 prodat.

Při aktuálním kurzu se akcie Replimune Group obchoduje za 17,51 EUR (19,23 USD).

Akcie Replimune Group (REPL) je kótována na 3 burzách, mimo jiné: NASDAQ (REPL), Frankfurt (7R8.F), München (7R8.MU).

Replimune Group Inc is a biopharmaceutical company specializing in the development of cell-based therapies for the treatment of cancer. The business model of Replimune Group is based on the development and commercialization of therapy products based on the technology of oncolytic viruses. This technology uses viruses that have been developed to infect and destroy tumor cells. Replimune Group has several products in its portfolio that are based on the fundamental technology of oncolytic viruses. These products are designed to enhance the body's immune response to tumor cells and directly destroy tumor cells. Replimune Group's products are targeted at a wide range of patients suffering from various types of cancer. Replimune Group operates its business activities in various divisions, including research and development, clinical trials, and marketing. The company has a strong research and development department that constantly develops new technologies and products to improve the quality and efficacy of its products. The company also conducts clinical trials to evaluate the efficacy of its products and ensure their safety. Through these studies, the company can also improve and optimize its products to provide better treatment for patients. The marketing of Replimune Group's products is done through the establishment of partnerships with other companies in the biotechnology and pharmaceutical sectors, as well as through direct marketing to hospitals and medical facilities. The company also has a sales department that focuses on marketing its products to oncologists, hematologists, and other specialists. Replimune Group has achieved a strong position in the field of oncolytic viruses in recent years and has become one of the leading companies in this field. According to estimates by the company, the market for oncolytic viruses is expected to grow exponentially in the coming years, providing Replimune Group with an excellent opportunity to further market and expand its products. Overall, the business model of Replimune Group Inc is focused on the development and marketing of products for the treatment of cancer based on the technology of oncolytic viruses. The company operates its business activities in various divisions, including research and development, clinical trials, and marketing. With this strategy, the company has achieved a strong position in the biotechnology and pharmaceutical sectors and has a promising future in oncology research and development.

Tržby nelze pro Replimune Group aktuálně vypočítat.

Zisk za Replimune Group činí -313,94 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.

Poměr ceny k zisku (P/E) Replimune Group je aktuálně -6,44. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Replimune Group.

Poměr P/S nelze pro Replimune Group aktuálně vypočítat.

Score kvality pro Replimune Group je 3/10.

ISIN Replimune Group je US76029N1063. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.

WKN Replimune Group je A2JQN1. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.

Ticker Replimune Group je REPL. Symbol tickeru se používá k obchodování akcií Replimune Group na burze.

Spravedlivá hodnotaTerminal
19,81 USD
Nadhodnocení/PodhodnoceníTerminal
Férovně oceněno
Průmysl
Biotechnologie
Počet akcií
Zaměstnanci
Růst tržeb Ø5 let
Růst EBIT Ø5 let
Růst čistého příjmu Ø5 let
Webové stránky replimune.com
Měna
USD
Veřejná nabídka akcií
20. 7. 2018
ISIN
US76029N1063
CUSIP
76029N106
SEDOL
BDDVW37
Tržní kapitalizace
1,59 Mld. USDSmall Cap
52týdenní rozpětí
PEG
—
P/E poměr
P/E poměr 2027
-11,93
P/E poměr 2028
-36,52
P/E poměr 2029
699,27
P/E poměr 2030
20,51
P/E poměr 2031
8,75
P/S
P/S poměr
58,85
EV/EBIT
—
P/B ratio
9,56
ROE (návratnost vlastního kapitálu)
ROA (návratnost aktiv)
ROCE (návratnost použitého kapitálu)
ROIC (návratnost investovaného kapitálu)
-113,03 %
Poslední aktualizace 20. 11. 2026 3:34

Replimune Group Ticker

FRANKFURT · 7R8.FMNICHOV · 7R8.MUNASDAQ · REPL

Replimune Group FIGI

REPL:US · BBG00L8Z22R1REPL:UA · BBG00L91XL62REPL:UC · BBG00L91XL71REPL:UN · BBG00L91XL99REPL:UP · BBG00L91XLB6REPL:UB · BBG00L91XLD4REPL:UM · BBG00L91XLG1REPL:UX · BBG00L91XLH0REPL:UD · BBG00L91XLN3REPL:UW · BBG00L91XLQ0REPL:UF · BBG00L91XLR9REPL:VY · BBG00L91XLS8

Všechny fundamentální údaje o Replimune Group v podrobné analýze

Naše analýzy akcií společnosti Replimune Group zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Replimune Group. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: